The Veterinary Cancer Society (VCS) Conference is the largest scientific meeting for veterinary oncology professionals globally. This year over 670 veterinary oncologists and associated health professionals attended the conference in Houston, USA. QBiotics' anticancer product tigilanol tiglate was the subject of two abstracts selected by the VCS scientific committee for presentation during the conference.

Dr Chad Johannes DVM, Diplomate ACVIM (SAIM, Oncology) presented the tigilanol tiglate canine mast cell tumour (MCT) pivotal field efficacy clinical trial results at two recent prestigious international congresses

The tigilanol tiglate canine dose characterisation study has been published as an original research article in the leading international journal, Frontiers in Veterinary Science. 

Australian life sciences company, QBiotics Group Limited (QBiotics) has closed its Group Share Offer on Friday 14 December 2018, with a total of $15,558,376 raised.

The Share Offer was scheduled to close today, 10 December 2018, at 5.00pm. The Board has decided to extend the Closing Date for Applications to 14 December 2018 at 5.00pm to allow share applications which are still in progress to be completed and included in the Offer.

QBiotics Group Limited has lodged a board-approved prospectus with the Australian corporate regulator the Australian Securities and Investments Commission (ASIC) on 26 October 2018.

The USA veterinary pivotal clinical study of tigilanol tiglate completes the data package for FDA and EMA submission.

QBiotics Group has signed an agreement with Virbac, one of the largest dedicated animal health companies globally, to supply, market and distribute its canine anticancer pharmaceutical, tigilanol tiglate.